Emerging human data, including small pilot studies showing good tolerability (e.g., intravenous infusions up to 20 mg with no adverse effects) and subjective improvements in conditions like chronic knee pain, further support its promise
Overall, the number of GLP-1 prescriptions increased sevenfold, from about 1 million in 2019 to over 8 million in 2024
Like many women over 40, the clients weight gain wasnt just about caloriesit was about hormonal imbalance
[19] [20] More serious but rare risks include pancreatitis (severe abdominal pain radiating to the back), gallbladder disease (right upper quadrant pain, fever, jaundice), and potential thyroid C-cell tumors (based on animal data)
Researchers are also exploring its potential in addressing chronic conditions, such as inflammatory disorders and degenerative diseases